The scope of the stress problem in aquaculture is enormous. Farmed fish face environmental fluctuations such as temperature swings, poor water quality, and salinity changes, alongside physiological challenges including handling, transportation, and overcrowding. Disease outbreaks and suboptimal feeding practices compound the burden. When fish perceive a threat, their bodies activate the hypothalamus-pituitary-interrenal axis, releasing cortisol and catecholamines—the primary stress hormones in teleosts. While these responses are adaptive in the short term, chronic activation leads to immunosuppression, impaired growth, altered behaviour, and oxidative damage. The metabolic demands of stressed fish rise sharply, dramatically increasing their need for amino acids to sustain cellular functions, support immune responses, and maintain overall health.

Among the most extensively studied functional amino acids is glutamine, a non-essential amino acid that becomes conditionally essential during stress. Glutamine serves as the primary energy source for rapidly dividing cells, particularly those of the immune system and gastrointestinal tract. When fish endure poor water quality or overcrowding, their glutamine reserves can deplete, compromising gut integrity and immune function. Supplementation with L-glutamine supports the growth and repair of enterocytes, the cells lining the intestine, preventing the translocation of pathogens and toxins into the bloodstream. Research cited in the review shows that dietary glutamine enhanced growth performance in Nile tilapia under chronic hyperosmotic stress by boosting antioxidant capacity and improving osmoregulation, although one study found no growth benefit for Atlantic salmon parr under high temperatures, underscoring that responses are species- and context-dependent.

Tryptophan offers perhaps the most striking example of how a single amino acid can reshape behaviour and physiology. As the precursor to serotonin, L-tryptophan influences mood, aggression, and the stress response itself. Serotonin exerts an inhibitory effect on the HPI axis, reducing cortisol release during challenging events such as transport or high stocking density. In Atlantic salmon, dietary supplementation with L-tryptophan or melatonin effectively mitigated stress-induced cortisol elevation, enhanced antioxidant defences, and improved osmoregulatory function following acute handling stress. Tryptophan also feeds the kynurenine pathway, which produces immunosuppressive metabolites that prevent excessive inflammation, and serves as a precursor to melatonin, the neurohormone governing sleep and circadian rhythms essential for recovery.

Arginine operates through an entirely different but equally vital mechanism: the L-arginine-nitric oxide pathway. The enzyme nitric oxide synthase converts arginine into nitric oxide, a signalling molecule that promotes vasodilation, improving blood flow, oxygen delivery, and waste removal in stressed tissues. Nitric oxide also modulates the sensitivity of inter-renal cells to adrenocorticotropic hormone and activates macrophages for pathogen defence. Beyond circulation, arginine supports ammonia detoxification through the urea cycle—critical when stress accelerates protein breakdown—and stimulates the proliferation of lymphocytes and macrophages. Studies in common carp, turbot, and Indian major carps have consistently shown that arginine supplementation improves stress resilience, lowers plasma cortisol, and enhances immune parameters.

The antioxidant dimension of amino acid nutrition centres on the glutathione system, and here cysteine and methionine take centre stage. Glutathione, a tripeptide composed of glutamine, cysteine, and glycine, is one of the most important intracellular antioxidants in fish, neutralizing the reactive oxygen species that accumulate during stress. Methionine, an essential sulfur-containing amino acid, is first converted to S-adenosylmethionine, a universal methyl donor, before feeding cysteine and ultimately glutathione synthesis. N-acetyl cysteine, a supplemental form of cysteine, facilitates de novo glutathione production by gamma-glutamylcysteine synthetase, the rate-limiting enzyme in the pathway, and accelerates glutathione regeneration through glutathione reductase. Histidine adds further antioxidant firepower, with its imidazole group capable of directly scavenging free radicals; histidine-deficient grass carp showed increased red blood cell fragility and reduced hypoxia tolerance.

Other amino acids play more specialized protective roles. Taurine, a sulfur-containing compound not incorporated into proteins, functions as a key osmolyte for marine and brackish water species, regulating ion transport across gill and kidney epithelial cells to maintain cellular osmotic balance during salinity fluctuations. It also stabilizes cell membranes, scavenges reactive oxygen species, and supports cardiac and nervous system function. Proline acts as an osmoprotectant shielding cellular membranes and proteins from damage, while contributing to collagen synthesis for tissue repair. Leucine, a branched-chain amino acid, stimulates the mTOR signalling pathway to preserve muscle protein during catabolic stress, though the review cautions that excessive leucine can suppress feed intake through amino acid sensing mechanisms in the brain. Glycine, the simplest amino acid, acts as an inhibitory neurotransmitter that calms nervous system excitability, reducing anxiety and aggression.

The review also highlights tyrosine, the precursor to the catecholamine stress hormones dopamine, norepinephrine, and epinephrine. Although tyrosine can be synthesized from phenylalanine, endogenous production may become insufficient during rapid growth or physiological stress. Studies in stinging catfish fingerlings identified an optimal phenylalanine-to-tyrosine ratio of roughly 65:35 for growth, antioxidant status, and digestive enzyme activity, while research in mrigal fingerlings established a total aromatic amino acid requirement of 21.5 grams per kilogram of diet, with tyrosine able to replace about 36 percent of the phenylalanine requirement. Tyrosine additionally supports melanin production for camouflage and cognitive functions aiding adaptation to changing environments.

Beyond individual mechanisms, the review emphasizes how amino acids intersect with energy metabolism and growth under stress. When carbohydrate and lipid reserves are depleted, fish increasingly rely on amino acids as fuel, converting them to glucose through gluconeogenesis or oxidizing them in the tricarboxylic acid cycle to generate ATP. Glutamine feeds the TCA cycle via alpha-ketoglutarate, while branched-chain amino acids are catabolized in skeletal muscle to produce acetyl-CoA and succinyl-CoA. This metabolic flexibility allows fish to maintain energy homeostasis, but only if dietary amino acid supplies are adequate. The authors argue that strategically timed supplementation—initiated before or during anticipated stress events—can prevent the muscle wasting, immunosuppression, and growth impairment that characterize chronic stress.

The practical implications extend well beyond fish welfare. As aquaculture shifts toward plant-based proteins for sustainability reasons, diets increasingly lack certain essential amino acids and contain anti-nutritional factors that stress the gut mucosa. Supplementing limiting amino acids such as lysine, methionine, and threonine restores amino acid balance, improves feed conversion ratios, and allows feed manufacturers to reduce fishmeal use, easing pressure on marine ecosystems. Improved nitrogen utilization also lowers nitrogenous waste output, a critical concern in intensive systems. Although crystalline amino acids carry a cost premium, the review concludes that their benefits—better stress tolerance, reduced mortality, and enhanced productivity—make them not merely a nutritional necessity but a genuine sustainability tool. Advances in microbial fermentation are further improving the affordability and environmental footprint of amino acid production, positioning these remarkable molecules at the heart of the future of responsible fish farming.

Subject of Research: The role of dietary amino acids in mitigating stress in aquaculture species

Article Title: Amino acids as functional nutrients in stress mitigation of aquatic species: mechanisms and applications in aquaculture

Article References: Chuphal, N., Malik, M. A., Kishore, P. S., & Mohanta, K. N. (2025). Amino acids as functional nutrients in stress mitigation of aquatic species: mechanisms and applications in aquaculture. Blue Biotechnology, 2(1), Article 20. https://doi.org/10.1186/s44315-025-00040-y

Image Credits: AI Generated

DOI: 10.1186/s44315-025-00040-y

Keywords: amino acids, aquaculture, fish stress, glutamine, tryptophan, arginine, taurine, glutathione, cortisol, osmoregulation, fish welfare, sustainable aquafeeds

The biology behind the problem is unforgiving. In genetically susceptible individuals carrying the HLA-DQ2 or HLA-DQ8 variants, dietary gluten triggers an adaptive immune cascade in which the enzyme tissue transglutaminase-2 chemically modifies gliadin peptides, provoking T-cell-driven destruction of the small intestinal lining. The result is villous atrophy and crypt hyperplasia, which shrink the absorptive surface of the gut and compromise the epithelial barrier. Diagnosis still requires positive serology, typically tissue transglutaminase IgA antibodies, together with a small-intestinal biopsy demonstrating villous damage, yet many people who self-diagnose or drift onto gluten-free diets have never been formally tested. Survey data suggest a global prevalence of about 1.4 percent, but an iceberg effect means most cases remain undiagnosed, and athlete-specific figures are almost nonexistent.

The numbers that do exist are telling. In a survey of 141 NCAA collegiate athletes, roughly 2.8 percent reported a physician diagnosis of celiac disease, while about 11.3 percent scored above the threshold for celiac-consistent symptoms, yielding odds of high-symptom status nearly 18 times higher than a general-population benchmark. The authors of the review caution that these figures rely on self-report, were drawn from a small convenience sample skewed toward white Midwestern athletes, and were compared against general-population rather than age-matched non-athlete controls. Still, the signal is hard to ignore, particularly because intense endurance exercise independently raises intestinal permeability, elevates serum zonulin, and upregulates the pore-forming tight junction protein claudin-2, mechanisms that converge with celiac pathology and could amplify risk or mask symptoms in genetically susceptible athletes through what researchers call Exercise-Induced Gastrointestinal Syndrome.

Even after diagnosis, the challenges multiply. The gold-standard treatment, a strict gluten-free diet, is nutritionally treacherous for people whose energy demands can reach 50 to 80 kilocalories per kilogram of body weight per day in endurance sports. Gluten-free products are frequently made from refined rice, tapioca, and potato starches, carry a higher glycemic index than wheat equivalents, and lack the iron and calcium fortification of conventional foods. Cross-contamination is a persistent hazard: studies of restaurant meals labeled gluten-free have found that roughly a third contain detectable gluten, and sensitive patients can suffer mucosal injury at daily exposures as low as 10 milligrams. The socioeconomic burden compounds the problem, with gluten-free foods costing 76 to 518 percent more than conventional equivalents in the United Kingdom, roughly double in Saudi Arabia, and up to 259 percent more on average in the United Arab Emirates, a burden that falls hardest on young, underfunded athletes who report food-related anxiety, social isolation, and meals skipped before competition.

The nutritional consequences are measurable and severe. Iron deficiency anemia affects up to 82 percent of celiac patients, and only about half restore their iron stores within a year of starting the gluten-free diet. Exercise compounds the deficit because the hormone hepcidin, which blocks iron absorption, remains elevated for up to six hours after training, cutting fractional iron absorption by more than a third. The review recommends timing iron-rich meals and supplements to the early morning, avoiding the three-to-six-hour post-exercise window, and pairing plant-based iron sources with vitamin C. Vitamin D deficiency, present in 8 to 88 percent of celiac patients, carries a staggering 23.3-fold higher risk of fifth metatarsal stress fractures at low serum levels, prompting suggested intakes of 2,000 to 6,000 IU per day for affected athletes. Calcium, magnesium, zinc, and B vitamins follow similar patterns of depletion driven jointly by malabsorption and the poor nutrient density of gluten-free substitutes.

The review also ventures into emerging territory. Sucrosomial iron formulations are preferred for athletes who cannot tolerate ferrous sulfate, and magnesium citrate or glycinate outperform oxide, whose bioavailability is a mere 4 percent. Genetic polymorphisms in the vitamin D-binding protein and receptor genes may explain why some athletes need substantially larger doses to reach the same serum 25-hydroxyvitamin D target of 30 to 50 nanograms per milliliter. On the supplement front, multi-strain probiotics containing Bifidobacterium breve and Lactobacillus plantarum reduced gastrointestinal symptoms 29 percent more than placebo in meta-analysis, while the alanyl-glutamine dipeptide, which survives gastric digestion and upregulates the tight junction proteins claudin and occludin, shows theoretical promise for a gut battered both by disease and by exercise-induced ischemia, though no trial has yet tested it in celiac athletes.

Perhaps the most underappreciated dimension is psychological. A meta-analysis found that people with celiac disease face roughly six-fold higher odds of anxiety and more than double the odds of depression, and collegiate athletes with more celiac-consistent symptoms reported poorer quality of life across physical, psychological, social, and environmental domains, along with greater depression and perceived stress. Childhood celiac disease carries a 19 percent increased risk of psychiatric disorder that persists into adulthood. Disordered eating is another red flag, with a pooled prevalence of nearly 9 percent and a significantly elevated risk of anorexia nervosa, a dangerous overlap in athletic populations where restrictive eating is already common. Even cognition is affected: neuroimaging studies have documented slower reaction times and white matter microstructural changes, the so-called brain fog, with direct implications for tactical decision-making and reaction-time precision in sport.

To bring order to this fragmented picture, the authors lay out a monitoring architecture that spans serology, biochemistry, and performance. Tissue transglutaminase IgA with total IgA remains the first-line screen, and clinicians are urged to test athletes presenting with unexplained fatigue, recurrent infections, refractory iron deficiency, or disproportionate stress fractures, noting that classic gastrointestinal symptoms may be absent in up to half of atypical cases. HLA-DQ2/DQ8 genotyping, with a negative predictive value above 99 percent when both alleles are absent, helps when athletes have already gone gluten-free. Blood sampling should be standardized, ideally in the morning after at least 48 hours of rest, to control for exercise-induced analytical variation, a detail routinely neglected in clinical practice. Dual-energy X-ray absorptiometry tracks bone mineral density and distinguishes genuine fat-free mass recovery from the fat gain and sarcopenic pattern that has been observed after a year on a gluten-free diet, while countermovement jump, handgrip strength, VO2 max, heart rate variability, and patient-reported symptom and quality-of-life scales complete the functional picture.

The review is candid about its limits. It is a structured narrative review conducted under the SANRA quality framework, not a systematic review with risk-of-bias assessment or meta-analysis, and much of its practical guidance extrapolates from the general celiac population, athletic populations without the disease, and mechanistic studies rather than from trials in biopsy-confirmed celiac athletes, of which there are almost none. Its recommendations should therefore be read as hypothesis-generating and practice-oriented rather than graded clinical guidelines. Still, the authors argue that no existing review has previously woven nutritional assessment, supplementation, and performance monitoring into a single athlete-centered framework, and they call for randomized controlled trials with biopsy-confirmed enrollment, adherence-verified comparator arms, and stratification by sport type, sex, age, and mucosal healing status.

The broader message resonates beyond the locker room. Celiac disease sits at the intersection of immunology, gastroenterology, exercise physiology, and psychology, and athletes amplify every one of those variables. If future research confirms that the physiological stress of training lowers the threshold for disease expression in genetically susceptible individuals, sports medicine will need athlete-specific epidemiology, screening checklists, and possibly an international registry to track adherence, biomarkers, and performance over time. For now, the review offers coaches, dietitians, and team physicians a practical warning: when an athlete’s engine keeps misfiring for reasons that training loads and talent cannot explain, it may be worth checking whether the fuel line itself is under attack.

Subject of Research: Integrated nutritional and performance monitoring for athletes with celiac disease

Article Title: An Integrated Nutritional and Performance Monitoring Framework for Athletes with Celiac Disease: A Structured Narrative Review

Article References: Yamani, O. B., Alghamdi, M. M., Zagzoog, A. M., Noorwali, E. A., Alotaibi, R. A., Alghannam, A. F., Aljaloud, K. S., Aragon, A. A., & Elsahoryi, N. A. (2026). An Integrated Nutritional and Performance Monitoring Framework for Athletes with Celiac Disease: A Structured Narrative Review. Current Research in Food Science, Article 101568. https://doi.org/10.1016/j.crfs.2026.101568

Image Credits: AI Generated

DOI: Not provided

Keywords: celiac disease, athletes, sports nutrition, gluten-free diet, iron deficiency, vitamin D, intestinal permeability, micronutrients, performance monitoring, probiotics, glutamine, athlete health

The scale of the problem the framework addresses is sobering. According to the ESPEN clinical nutrition guidelines cited in the review, tumor-induced metabolic disturbances and treatment-related toxicities contribute to malnutrition in a large proportion of patients, and an estimated 10 to 20 percent of people with cancer die from malnutrition rather than from the tumor itself. Recent meta-analyses report that severe malnutrition affects roughly 20 percent of cancer patients, with prevalence climbing to 46 percent among hospitalized patients assessed using the GLIM criteria. The consequences ripple across every dimension of care: a global multicenter study found that one third of patients undergoing gastrointestinal cancer surgery were severely malnourished, a condition linked to significantly higher 30-day postoperative mortality, while a separate meta-analysis showed that GLIM-defined malnutrition nearly triples the risk of death within one year compared with well-nourished patients.

The authors contend that the reason conventional nutritional support often falls short is structural rather than conceptual. Standard practice includes individualized dietary counseling, oral nutritional supplements, enteral nutrition, and parenteral nutrition, with the oral and enteral routes preferred whenever the gastrointestinal tract is functional. These interventions can improve intake, weight, and some patient-reported outcomes, but their effects vary widely depending on tumor type, baseline nutritional status, inflammatory burden, and treatment phase. Perioperative immunonutrition containing arginine, omega-3 fatty acids, and nucleotides has shown benefit in selected surgical populations, yet most existing strategies remain single-component or non-targeted. Cancer-associated wasting, by contrast, is a tangled web of metabolic reprogramming, systemic inflammation, immune dysfunction, gut-barrier injury, microbiota disturbance, and treatment toxicity, and no single nutrient can plausibly address all of these dimensions at once.

Enter the traditional Chinese medicine concept of prescription compatibility. In classical Chinese formularies, Jun herbs target the primary pathological mechanism, Chen herbs provide supportive and synergistic effects, Zuo herbs mitigate toxicity or moderate adverse effects, and Shi herbs guide the actions of the principal components and harmonize the whole formulation. The authors are careful to frame this as a translational metaphor rather than proof of pharmacological equivalence between herbs and nutrients. Still, they argue, the compatibility logic is unusually well suited to oncology nutrition because malnourished cancer patients often simultaneously face insufficient intake, inflammation, insulin resistance, skeletal muscle loss, mucosal injury, diarrhea, micronutrient deficiency, anxiety, and fatigue. A hierarchical structure helps clinicians distinguish non-negotiable foundations from optional adjuncts and prevents the substitution of essential energy and protein support with poorly evidenced supplements.

In the proposed model, Jun nutrients constitute the foundational substrate layer: proteins, carbohydrates, and fats. Protein is the centerpiece, with guidelines recommending at least 1.0 gram per kilogram of body weight per day in cancer patients, ideally raised to 1.2 to 1.5 grams per kilogram. Review evidence suggests that daily intake above 1.4 grams per kilogram during treatment helps preserve muscle mass, while intake below 1.2 grams is commonly associated with muscle loss. The PRIMe trial in colorectal cancer explored a high-protein intake of 2.0 grams per kilogram during chemotherapy, with preliminary findings suggesting that roughly half of the patients maintained or improved muscle mass. Carbohydrates serve as an efficient energy source that spares protein from oxidation, with complex carbohydrates and dietary fiber from whole grains, fruits, and vegetables improving insulin sensitivity and reducing inflammatory mediators, whereas refined sugars and high glycemic loads warrant caution given the Warburg effect and the possible association of hyperglycemia with tumor growth and invasion. Fats supply concentrated energy and essential fatty acids, with priority given to monounsaturated and polyunsaturated sources such as olive oil, nuts, and deep-sea fish oil. A randomized controlled trial showed that daily supplementation with six grams of medium-chain triglycerides improved muscle strength and daily functioning in frail older adults within three months, suggesting a potential role against cancer-related wasting, and Mediterranean-style, olive-oil-rich dietary patterns have been linked to substantially reduced breast cancer incidence.

Chen nutrients are the reinforcing layer, selected when a patient shows inflammation, muscle wasting, or impaired anabolic response. The prototype is the omega-3 polyunsaturated fatty acids EPA and DHA, which suppress pro-inflammatory eicosanoids and cytokines, inhibit nuclear factor-kappa B activation, and enhance insulin sensitivity. Clinical studies report that fish oil supplementation improves appetite, increases skeletal muscle mass, and stabilizes body weight in advanced cancer, and a meta-analysis found that oral supplements containing omega-3 fatty acids increased body weight in patients with cancer cachexia by an average of approximately 1.22 kilograms alongside significant improvements in quality-of-life scores. Branched-chain amino acids, particularly leucine, and its metabolite beta-hydroxy-beta-methylbutyrate, activate the mTOR pathway and suppress muscle protein breakdown, respectively. A meta-analysis in hepatocellular carcinoma showed that perioperative supplementation reduced postoperative infections and ascites and produced average weight gains of nearly two kilograms. L-carnitine completes this tier by transporting long-chain fatty acids into mitochondria, suppressing proteolysis through AKT and FOXO3a signaling, and, in early clinical work, improving fatigue, body composition, and quality of life in patients with advanced cancer.

Zuo nutrients act as coordinating adjuncts that protect the gut and buffer treatment toxicity. Probiotics such as Lactobacillus and Bifidobacterium species, together with prebiotics like inulin, support intestinal barrier function and short-chain fatty acid production. Systematic reviews indicate that probiotic use among patients receiving chemotherapy or radiotherapy reduces the risk of diarrhea of any grade by approximately 65 percent and severe diarrhea by about 57 percent, while another meta-analysis reported a roughly 30 percent reduction in chemotherapy-induced diarrhea and a halving of severe cases, alongside markedly lower rates of oral mucositis. Glutamine, a conditionally essential amino acid during physiological stress, fuels intestinal epithelial cells, promotes mucosal repair, and reduces permeability and bacterial translocation. Meta-analyses show that glutamine nearly halves the risk of grade III to IV oral mucositis from chemotherapy or radiotherapy, prompting MASCC to list oral glutamine as an optional prophylactic measure, and supplementation has also reduced chemotherapy-induced diarrhea in colorectal cancer patients by roughly 35 percent.

Shi nutrients, the guiding cofactors, include vitamins, trace elements, and coenzymes that make the entire system work. B vitamins drive energy metabolism and hematopoiesis, vitamins A, C, and E support epithelial integrity and antioxidant defense, and vitamin D carries endocrine and immunomodulatory functions, with higher serum levels associated with longer survival in patients receiving immune checkpoint inhibitors. Trace elements matter enormously: in a retrospective study of gynecological malignancies, serum zinc declined significantly after surgery and chemoradiotherapy, and zinc deficiency was 4.8 times more likely in patients whose tumors recurred, with levels below 61 micrograms per deciliter independently predicting recurrence. Iron, folate, and vitamin B12 are essential for erythropoiesis, though excessive iron must be avoided for its possible tumor-promoting effects. Coenzyme Q10, a mitochondrial electron carrier, has shown in breast cancer trials that 100 milligrams daily for six to twelve weeks significantly reduced circulating VEGF and IL-8 and suppressed matrix metalloproteinase activity, suggesting a possible role in easing fatigue and inflammation.

The framework’s greatest practical promise may lie in its adaptability to specific cancers and complications. In breast cancer, vitamin D and calcium anchor skeletal health during endocrine therapy while glutamine and probiotics buffer chemotherapy toxicity; in lung cancer, anti-inflammatory omega-3 fatty acids and branched-chain amino acids counter the cachexia that affects so many patients at diagnosis; in esophageal cancer, tube-fed enteral nutrition and perioperative immunonutrition with arginine and fish oil reduce postoperative infections; in hepatocellular carcinoma, branched-chain amino acid-enriched formulas meet protein needs while limiting ammonia-related metabolic burden. The authors stress that traditional Chinese medicine formulas, including Huangqi Sijunzi, Liujunzi, and Buzhong Yiqi decoctions, should complement rather than replace standard oncologic nutrition care, and they acknowledge that randomized controlled trials of structured nutrition-TCM integrative strategies remain limited. Looking ahead, they propose that patient stratification using metabolomics, inflammatory markers, and microbiome profiles, combined with nutritional informatics and systems modeling, could transform this ancient hierarchy into testable combination hypotheses and dosing rules, moving supportive oncology from experience-based practice toward genuinely data-driven, precision nutritional medicine.

Subject of Research: Application of the traditional Chinese medicine principle of Jun-Chen-Zuo-Shi to individualized nutritional therapy for cancer-associated malnutrition and cachexia.

Article Title: “Jun-Chen-Zuo-Shi” – the Chinese medical perspective on clinical oncology nutritional therapy

Article References: Lin, S., Li, B., & Yao, Q. (2026). “Jun-Chen-Zuo-Shi” – the Chinese medical perspective on clinical oncology nutritional therapy. Holistic Integrative Oncology, 5(1), Article 62. https://doi.org/10.1007/s44178-026-00282-9

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00282-9

Keywords: cancer cachexia, malnutrition, Jun-Chen-Zuo-Shi, traditional Chinese medicine, oncology nutrition, omega-3 fatty acids, branched-chain amino acids, glutamine, probiotics, micronutrients, nutritional therapy, lean body mass

The research team set out to answer a deceptively simple question: when prostate cancer cells stop responding to enzalutamide, what has actually changed inside them? Resistance is often described in terms of genetic mutations in the androgen receptor or amplification of the receptor gene itself, but these alterations explain only a fraction of clinical cases. Increasingly, cancer biologists have recognized that drug-tolerant cells frequently survive by adjusting their metabolism, the network of chemical reactions that converts nutrients into energy, building blocks and signaling molecules. Because metabolic rewiring is a physical requirement for survival rather than an optional accessory, it may represent a more universal and more druggable hallmark of resistance than any single mutation.

To capture that rewiring comprehensively, the investigators applied a multi-omic pipeline to paired models of enzalutamide-sensitive and enzalutamide-resistant prostate cancer cells. Transcriptomic sequencing revealed which genes were switched on or off; proteomic mass spectrometry quantified the enzymes actually present in the cells; and metabolomic profiling measured the small molecules, sugars, amino acids and lipids that flow through the metabolic network. The power of this approach lies in its convergence. A change in a single data type can be misleading, but when altered messenger RNA, altered protein and altered metabolite levels all point to the same pathway, the evidence becomes difficult to dismiss.

The analysis converged on several interconnected metabolic shifts. Resistant cells displayed a marked reorganization of lipid metabolism, upregulating pathways for fatty acid synthesis and elongation while also altering cholesterol handling. This makes biological sense for prostate cancer in particular, because the androgen receptor does more than respond to testosterone; it also regulates genes involved in lipid acquisition and synthesis, and membrane lipid composition influences receptor signaling at the cell surface. By boosting de novo lipogenesis, resistant cells appear to buffer themselves against the loss of androgen-driven lipid programs that enzalutamide imposes, effectively rebuilding a supply line the drug was designed to cut.

Energy metabolism showed equally telling changes. Profiling of central carbon metabolism indicated that resistant cells leaned more heavily on glycolysis and on glutamine-fueled anaplerosis, the process by which the amino acid glutamine tops up the tricarboxylic acid cycle with carbon. Mitochondrial oxidative phosphorylation was also reconfigured, with altered expression of electron transport chain components suggesting a shift in how resistant cells balance ATP production against the generation of biosynthetic precursors. These are not idle adjustments. Rapidly dividing tumor cells must simultaneously produce energy, reduce cellular building blocks and maintain antioxidant defenses, and the observed pattern is characteristic of cells that have traded metabolic efficiency for metabolic flexibility.

Crucially, the study did not stop at description. The researchers tested whether the metabolic alterations they detected could be exploited therapeutically. Inhibiting key enzymes in the upregulated lipid synthesis pathway reduced the viability of enzalutamide-resistant cells more severely than that of their drug-sensitive counterparts, indicating a genuine dependence rather than incidental correlation. Similar experiments targeting glutamine metabolism and mitochondrial respiration produced the same pattern of selective vulnerability. When metabolic inhibitors were combined with continued enzalutamide treatment, the effect was additive, and in some settings synergistic, meaning that the resistant cells could be resensitized to the drug they had learned to ignore.

The concept underlying these results is known as collateral vulnerability. When cancer cells evolve resistance to one pressure, the evolutionary path they take often creates new dependencies that did not exist before. A cell that ramps up fatty acid synthesis to survive androgen receptor blockade, for example, becomes exquisitely sensitive to inhibitors of that synthesis pathway. Because these dependencies are consequences of the resistance program itself, they are less likely to be bypassed by further tumor evolution without a significant fitness cost. This is the same logic that has made synthetic lethal strategies, such as PARP inhibition in DNA repair-deficient tumors, one of the most productive ideas in modern oncology, now extended into the metabolic arena.

The findings carry practical implications for the clinic. Enzalutamide resistance currently marks a transition point at which patients move toward chemotherapy, androgen biosynthesis inhibitors or, for those with suitable tumor biology, radioligand therapy. If metabolic vulnerabilities of the kind identified here can be confirmed in patient-derived models and ultimately in clinical trials, metabolic inhibitors could be layered onto existing regimens at the first sign of rising prostate-specific antigen during enzalutamide treatment, potentially delaying or preventing overt resistance. The study also raises the possibility of using metabolic imaging or circulating metabolite profiles as biomarkers, allowing clinicians to detect the metabolic shift before the tumor has fully escaped hormonal control.

Several caveats temper the enthusiasm. Cell line models, even well-characterized ones, capture only part of the complexity of human tumors, which contain stromal cells, immune infiltrates, variable oxygen and nutrient availability and extensive intratumoral heterogeneity. Metabolic phenotypes are notoriously context-dependent, shaped by the culture conditions in which cells are grown and by the specific evolutionary path each resistant line has taken. The authors’ use of multiple paired models and convergent multi-omic evidence strengthens their conclusions, but translating these dependencies into patients will require validation in organoids, xenografts and ultimately biopsy material from men whose disease has progressed on enzalutamide. Dose-limiting toxicities of metabolic inhibitors, particularly those affecting normal tissues with high metabolic flux, will also need careful management.

Nevertheless, the study represents a meaningful step toward a more complete picture of how prostate cancer defeats one of its most important therapies. By treating metabolism not as background housekeeping but as a central player in drug resistance, and by interrogating that metabolism with layers of molecular data rather than single measurements, the work provides both a mechanistic map and a practical target list. For the growing population of men living with castration-resistant prostate cancer, the hope is that the very adaptations tumors use to survive enzalutamide will become the handles by which the next generation of treatments pulls them back into vulnerability.

Subject of Research: Metabolic rewiring in enzalutamide-resistant prostate cancer identified through integrated transcriptomic, proteomic and metabolomic profiling

Article Title: Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer

Article References: Lee, O., Fidelito, G., Zhao, Q., Liu, B., Choi, H., Taylor, R. A., & Watt, M. J. (2026). Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03332-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03332-3

Keywords: prostate cancer, enzalutamide, drug resistance, multi-omics, metabolism, lipid metabolism, glutamine, androgen receptor, oxidative phosphorylation, collateral vulnerability, cancer therapeutics, Cell Death Discovery